Holen Sie sich die Stockscreener-App
37.11
1.56%
0.57
Handel nachbörslich:
36.43
-0.68
-1.83%
Schlusskurs vom Vortag:
$36.54
Offen:
$36.43
24-Stunden-Volumen:
5.48M
Relative Volume:
0.69
Marktkapitalisierung:
$26.81B
Einnahmen:
$8.26M
Nettoeinkommen (Verlust:
$-397.91M
KGV:
-73.69
EPS:
-0.5036
Netto-Cashflow:
$-758.56M
1W Leistung:
+0.84%
1M Leistung:
+0.35%
6M Leistung:
+33.63%
1J Leistung:
+101.58%
1-Tages-Spanne:
$36.13
$37.13
1-Wochen-Bereich:
$35.66
$38.49
52-Wochen-Spanne:
$18.32
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
37.11 | 26.81B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-09-17 | Eingeleitet | Stifel | Buy |
| 2026-03-20 | Eingeleitet | Bernstein | Outperform |
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Melissa Epperly Receives 513 Roivant Shares, Retains 15,351 After Tax Withholding Net Settlement - Kalkine Media
Taxes account for 116 shares of a 513-share director award at Roivant Sciences (ROIV). - Stock Titan
An 810-share award is fully vested for Roivant Sciences (ROIV) director Oren Ilan. - Stock Titan
A director receives 383 Roivant Sciences (ROIV) shares, with 77 withheld for taxes. - Stock Titan
Planned share sales at Roivant Sciences (ROIV) include 14,144 shares at $35.42. - Stock Titan
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - GlobeNewswire Inc.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) - GlobeNewswire Inc.
Form 144 Roivant Sciences Ltd. For: 20 October By Investing.com - Investing.com Nigeria
19,976 shares withheld for taxes leave Roivant Sciences (ROIV) CIO holding 18.6M shares. - Stock Titan
At $33.53 each, 34,638 shares were withheld for CEO taxes at Roivant Sciences (ROIV). - Stock Titan
An officer proposes selling 200,000 Roivant Sciences (NASDAQ: ROIV) shares under a trading plan. - Stock Titan
Roivant Sciences (ROIV) Tests Brepocitinib Hopes As The Stock Looks Fully Valued - Simply Wall Street
Form 144 Roivant Sciences Ltd. For: 20 October By Investing.com - Investing.com South Africa
Roivant Sciences (ROIV) Rises 3.07% to $34.56, Trading Near Midpoint of Support and ResistanceVirgin POC - https://www.dars.gov.et/
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run - Yahoo Finance
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. - Stock Titan
Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares. - Stock Titan
CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes. - Stock Titan
Vesting triggers withholding of 46,879 shares from Roivant Sciences (ROIV) President Mayukh Sukhatme. - Stock Titan
After exercising $3.85 options, Eric Venker sells shares in Roivant Sciences (ROIV). - Stock Titan
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Nigeria
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant (ROIV) director uses shares to cover taxes - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Venker Eric | Officer |
Oct 20 '26 |
Proposed Sale |
35.12 |
200,000 |
7,023,513 |
0 |
| Venker Eric | President & Immunovant CEO |
Oct 20 '26 |
Sale |
35.11 |
200,000 |
7,022,668 |
1,399,154 |
| Epperly Melissa B, | Director |
Oct 01 '26 |
Option Exercise |
4.46 |
17,750 |
79,165 |
32,704 |
| Epperly Melissa B, | Director |
Oct 01 '26 |
Sale |
36.10 |
17,750 |
640,861 |
14,954 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Sale |
36.62 |
200,000 |
7,324,000 |
1,599,154 |
| Venker Eric | Officer |
Sep 30 '26 |
Proposed Sale |
36.62 |
200,000 |
7,323,556 |
0 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,799,154 |
| Fitzgerald Meghan | Director |
Sep 15 '26 |
Sale |
39.74 |
5,112 |
203,152 |
36,108 |
| MEGHAN FITZGERALD | Officer |
Sep 15 '26 |
Proposed Sale |
41.02 |
5,112 |
209,694 |
0 |
| MELISSA EPPERLY | Director |
Sep 15 '26 |
Proposed Sale |
41.02 |
22,688 |
930,662 |
0 |
0.70%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):